Cargando…

Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway

The Period2 (Per2) gene is an essential component of the mammalian circadian clock and is strongly linked to glioma occurrence and its response to radiotherapy. Here, we examined the role of Per2 in the response to X-ray-induced DNA damage in U343 glioma cells and in a mouse cancer model. Following...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhanfeng, Niu, Chengquan, Wang, Hechun, Xia, Jun, Wang, Lijian, Zhang, Dede, Ma, Wenbin, Liu, Lei, Yin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053655/ https://www.ncbi.nlm.nih.gov/pubmed/27036047 http://dx.doi.org/10.18632/oncotarget.8439

Ejemplares similares

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

PER2 inhibits proliferation and stemness of glioma stem cells via the Wnt/β-catenin signaling pathway
por: Ma, Dede, et al.
Publicado: (2020)

Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Circadian genes Per1 and Per2 increase radiosensitivity of glioma in vivo
por: Zhanfeng, Niu, et al.
Publicado: (2015)

ATRT-08. TARGETING THE TP53-MDM2 ENHANCES RADIATION SENSITIVITY IN ATRT
por: Alimova, Irina, et al.
Publicado: (2021)

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women
por: Zając, Agnieszka, et al.
Publicado: (2014)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
por: Drummond, Catherine J., et al.
Publicado: (2016)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
por: Foulkes, W. D., et al.
Publicado: (1995)

TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
por: Xu, Cheng, et al.
Publicado: (2021)

Plasma Erythropoietin, IL-17A, and IFNγ as Potential Biomarkers of Motor Function Recovery in a Canine Model of Spinal Cord Injury
por: Zhang, Lijian, et al.
Publicado: (2020)

TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients
por: Di Vuolo, Valeria, et al.
Publicado: (2011)

Investigation of ATM, TP53 and MDM2 polymorphisms and their association with outcome of radiotherapy for prostate cancer
por: Cintra, Hellen S, et al.
Publicado: (2013)

Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms
por: Cabezas, Maria, et al.
Publicado: (2019)

Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors
por: Alimova, Irina, et al.
Publicado: (2022)

Individual and combined effect of TP53, MDM2, MDM4, MTHFR, CCR5, and CASP8 gene polymorphisms in lung cancer
por: Stumbryte, Ausra, et al.
Publicado: (2017)

Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
por: Hori, Yasuki, et al.
Publicado: (2015)

Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation
por: Tracz-Gaszewska, Zuzanna, et al.
Publicado: (2017)

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022)

Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling
por: Wang, Xiaoxuan, et al.
Publicado: (2021)

Circadian Period 2 (Per2) downregulate inhibitor of differentiation 3 (Id3) expression via PTEN/AKT/Smad5 axis to inhibits glioma cell proliferation
por: Zhang, Yifan, et al.
Publicado: (2022)

Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population
por: Xiao, Mang, et al.
Publicado: (2010)

Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer
por: YONEDA, TOMOKO, et al.
Publicado: (2013)

Correction: Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
Publicado: (2015)

The important role of MDM2, RPL5, and TP53 in mycophenolic acid-induced cleft lip and palate
por: Lin, Yangyang, et al.
Publicado: (2021)

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer
por: Jindal, Tanya, et al.
Publicado: (2023)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability
por: Wen, Weihong, et al.
Publicado: (2013)

The MDM2-p53 pathway revisited
por: Nag, Subhasree, et al.
Publicado: (2013)

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
por: McGraw, Kathy L., et al.
Publicado: (2015)

Associations of MDM2 rs2279744 and TP53 rs1042522 polymorphisms with cervical cancer risk: A meta-analysis and systematic review
por: Yu, Meijia, et al.
Publicado: (2022)

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016)

Loss of FBXO7 results in a Parkinson's‐like dopaminergic degeneration via an RPL23–MDM2–TP53 pathway
por: Stott, Simon RW, et al.
Publicado: (2019)

ODP281 JDP2 Interacts with MDM2 and Decreases MDM2-Mediated p53 Repression
por: Yang, William, et al.
Publicado: (2022)

TP53 and MDM2 Gene Polymorphisms, Gene-Gene Interaction, and Hepatocellular Carcinoma Risk: Evidence from an Updated Meta-Analysis
por: Peng, Qiliu, et al.
Publicado: (2013)

MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53
por: Makii, Chinami, et al.
Publicado: (2016)

Uncommon non-oncogenic HPV genotypes, TP53 and MDM2 genes polymorphisms in HIV-infected women in Southern Brazil
por: Entiauspe, Ludmila Gonçalves, et al.
Publicado: (2014)

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
por: Pairawan, Seyed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v0via41orh7ar2isr8pik5q9s6